Mesoblast's (ASX:MSB) CEO has detailed plans to work with partner Teva to commercialise off-the-shelf adult dental pulp stem cells (DPSCs) for neurological conditions. [ + ]

Incoming CEO and present COO of Prima BioMed, Matt Lehman, will refocus the company’s efforts on progressing CVac through clinical trials. [ + ]

Since February this year, John Morris Scientific has been conducting a campaign to locate the oldest working Gilson pipette in Australia and New Zealand. The winner, Denise Lupton, Chief Technician at the University of Western Australia, submitted a Gilson P200, manufactured prior to 1979. [ + ]

pSivida (ASX:PVA) has received a US patent for a new microdrug delivery device which will be used with its Medidur implant, an injectable, sustained-release drug delivery system. [ + ]

AusBiotech members in Western Australia (WA) this week welcome the appointment of a new industry development officer (IDO), Michelle Nicolson to support the work of the WA Branch Committee. [ + ]

BioDiem (ASX:BDM) has been granted a license for vaccine technology developed at ANU with applications for diseases including dengue fever. [ + ]

New funding from the Health Research Council has continued support for the Centre for Free Radical Research at the University of Otago, Christchurch, with a grant of $4.2 million over the next three years. [ + ]

The degree of genetic difference to a tumour rapidly decimating the ranks of Tasmanian devils is not a factor in their likelihood of contracting the disease, according to research led by the University of Sydney. [ + ]

Thermo Fisher Scientific has signed an asset purchase agreement with Nephromics, which includes a patent licence for exclusive rights to use PlGF (Placental Growth Factor) for the diagnosis of pre-eclampsia or eclampsia. [ + ]

Researchers from Murdoch University have assisted in a groundbreaking discovery which could lead to the dramatic improvement of drug safety. [ + ]

Allied Healthcare (ASX:AHZ) has lodged an application for a CE Mark for CardioCel, the cardiovascular patch developed by subsidiary Celxel. [ + ]

Phosphagenics (ASX:POH) said in vitro tests of new adhesives in its TPM/oxycodone patch show superior performance to that developed by patch partner 3M. [ + ]

The NSW government has responded to the NSW Health and Medical Research Strategic Review 2012 by committing $70 million to implement many of the report’s recommendations. [ + ]

A memorandum of understanding (MOU) between AusBiotech and the Hong Kong Biotechnology Organisation (HKBIO) is expected to boost cooperation between Hong Kong and Australia. [ + ]

The US Pharmacopeial Convention (USP) has announced two new standards related to elemental impurities: General Chapters <232> Elemental Impurities - Limits and <233> Elemental Impurities - Procedures. The standards provide procedures for the detection of selected impurities in drug products based on modern analytical methods, as well as acceptable limits for their presence based on toxicity data and exposure levels. [ + ]